Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study

Απλή σελίδα τεκμηρίου
dc.contributor.authorChristodolou, C.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorKouvatseas, G.en
dc.contributor.authorPagdatoglou, K.en
dc.contributor.authorPalamidas, F.en
dc.contributor.authorNikolaidis, C.en
dc.contributor.authorAngelidou, M.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorSkarlos, D. V.en
dc.date.accessioned2015-11-24T18:56:21Z
dc.date.available2015-11-24T18:56:21Z
dc.identifier.issn0250-7005-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19025
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/therapeutic useen
dc.subjectCarboplatin/administration & dosageen
dc.subjectCarcinoma, Small Cell/complications/*drug therapy/pathology/*radiotherapyen
dc.subjectClinical Trials as Topicen
dc.subjectEthnic Groupsen
dc.subjectEtoposide/administration & dosageen
dc.subjectFemaleen
dc.subjectGreeceen
dc.subjectHumansen
dc.subjectLung Neoplasms/complications/*drug therapy/pathology/*radiotherapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMultivariate Analysisen
dc.subjectNeoplasm Stagingen
dc.subjectPrognosisen
dc.subjectRisk Factorsen
dc.subjectSex Factorsen
dc.subjectSuperior Vena Cava Syndrome/complicationsen
dc.subjectSurvival Rateen
dc.subjectTreatment Outcomeen
dc.titlePrognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group studyen
heal.abstractBACKGROUND: Prognostic factors among Greek patients with SCLC were evaluated. PATIENTS AND METHODS: Data from 516 patients with SCLC treated by the Hellenic Cooperative Oncology Group were analyzed. Multivariate analysis was performed. RESULTS: Complete response (CR) was achieved in 26.8% and partial response in 40.1% of patients. The median duration of response was 7.4 months, the median survival 10.5 months and the 2-year survival rate 12%. The stage of the disease was a dominant prognostic factor for survival and response. PS 0-1 was a major prognostic factor for survival, duration of response and CR. Female gender was a favorable predictor for CR. Superior vena cava syndrome was a poor prognostic factor for survival and duration of response. Weight loss and age > or = 60 were poor predictors for response. The sites of metastases affected survival, duration of response and response. Normal alkaline phosphatase was a favorable prognostic factor for survival, duration of response and response. Normal lactate dehydrogenase and thoracic irradiation were favorable prognostic factors for survival and duration of response.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12552988-
heal.journalNameAnticancer Resen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2002-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ